Assessing LivaNova (LIVN) Valuation After Strong One Year Shareholder Returns

Why LivaNova Stock Is on Investors’ Radar

LivaNova (LIVN) has drawn attention after recent trading, with the shares closing at $64.70. For context, the stock shows a 1 day return of 0.86% and a past week move of 8.87%.

Over the past month the stock is down 1.87%, while over the past 3 months it is up 2.11%. Year to date, LivaNova’s total return is 6.70%, and the 1 year total return stands at 61.79%.

See our latest analysis for LivaNova.

Recent trading has been choppy, with a 1 day share price return of 0.86% and a 30 day share price return of 1.87% contrasting with a much stronger 1 year total shareholder return of 61.79%. This indicates momentum built over the longer stretch, even if shorter term sentiment has cooled.

If LivaNova’s moves have you rethinking where growth in medical technology might come from next, it could be a good time to scan 31 healthcare AI stocks for fresh ideas beyond a single name.

With LivaNova trading at $64.70, some investors are pointing to a roughly 24% gap to the average analyst target and a modelled intrinsic discount of about 34%. Is this genuine value on offer, or is the market already baking in future growth?

Most Popular Narrative: 11.4% Undervalued

At $64.70, the most followed narrative pegs LivaNova’s fair value at about $73, leaving a double digit gap that hinges on future execution and profitability.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Read the complete narrative.

Curious what has to happen for that higher price to make sense? The narrative leans on steadier revenue gains, rising margins, and a future earnings multiple more typical of premium medical device names.

Result: Fair Value of $73 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on reimbursement support and product uptake continuing, while cost pressures, competition or regulatory setbacks could quickly challenge those fair value assumptions.

Find out about the key risks to this LivaNova narrative.

Next Steps

If this mix of optimism and caution leaves you unsure, take a closer look at the numbers yourself and form your own view. You can start with 4 key rewards.

Ready to hunt for more ideas?

Do not stop at one stock when a whole range of opportunities is already mapped out for you by the Simply Wall St screener tools.

• Target potential mispricings by scanning our 47 high quality undervalued stocks that pair financial quality with attractive prices.
• Prioritise resilience by reviewing 77 resilient stocks with low risk scores that score well on stability and downside protection.
• Spot early opportunities by checking the screener containing 24 high quality undiscovered gems before they land on everyone else’s watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com